KLKB1: Plasma kallikrein
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
Participates in the surface-dependent activation of blood coagulation.
- Drugs that act on it: 6
- Approved: 5
- In phases 1 to 3: 1
- Sponsors: 4
Who Is On It, and How Far Along
Every drug ChEMBL records acting on KLKB1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule
- Antibody
- Protein or peptide
- Other
Approved5
Phase 31
Phase 20
Phase 10
Sponsors
Drugs on this target per company: the US application holder, else the industry sponsor leading the most of its trials.
- BioCryst Pharmaceuticals233%
- Takeda Pharmaceuticals USA233%
- Bayer117%
- IMMUNOe Research Centers117%
Modalities
Drugs on this target by ChEMBL molecule type.
- Small molecule233%
- Antibody117%
- Protein or peptide233%
- Other117%
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Plasma kallikrein inhibitor.| Human C1-ESTERASE inhibitor | Approved | IMMUNOe Research Centers | Protein or peptide | Inhibitor | — | 5 | — |
| Lanadelumab | Approved | Takeda Pharmaceuticals USA | Antibody | Inhibitor | — | 3 | — |
| Aprotinin | Approved | Bayer | Other | Inhibitor | — | 2 | Withdrawn |
| Berotralstat | Approved | BioCryst Pharmaceuticals | Small molecule | Inhibitor | — | 2 | — |
| Ecallantide | Approved | Takeda Pharmaceuticals USA | Protein or peptide | Inhibitor | — | 0 | Boxed warning |
| Avoralstat | Phase 3 | BioCryst Pharmaceuticals | Small molecule | Inhibitor | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 12 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Inherited prekallikrein deficiency
- 0.72
- Prekallikrein deficiency
- 0.67
- Blood coagulation disease
- 0.51
- Angioedema
- 0.45
- Serum lipopolysaccharide activity
- 0.42
- Heart disorder
- 0.41
- Hemorrhage
- 0.39
- Hemorrhagic disease
- 0.37
- Cardiovascular disorder
- 0.36
- Coronary artery calcification
- 0.36
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2000, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P03952, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets